公开(公告)号：US20160313300A1

公开(公告)日：2016-10-27

申请号：US15101869

申请日：2014-12-05

申请人： CELGENE CORPORATION

发明人： Matthew William Burnell Trotter ,  Patrick Hagner ,  Courtney G. Havens ,  Rajesh Chopra ,  Anita Gandhi ,  Anke Klippel ,  Maria Yinglin Wang ,  Mike Breider ,  Suzana Sturlini Couto ,  Yan Ren ,  Paul Hollenbach ,  Kyle MacBeth

IPC分类号： G01N33/50 ,  C12Q1/68 ,  A61K31/5377 ,  G01N33/68 ,  A61K31/454 ,  A61K31/517 ,  G01N33/574 ,  A61K38/21

摘要： Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

摘要翻译： 在一些实施方案中，提供了使用某些与诸如Aiolos，Ikaros，干扰素（IFN）和IFN途径蛋白（酪蛋白激酶1，α1（CSNK1A1）和ZFP9）相关的蛋白相关蛋白作为生物标志物的方法 在预测和监测患有各种疾病和障碍的患者（例如弥漫性大B细胞淋巴瘤（DLBCL），多发性骨髓瘤（MM），骨髓增生异常综合征（MDS）和急性髓细胞性疾病的患者中的某些化合物的临床敏感性和治疗反应 白血病（AML））和IFN相关疾病。 本文还在某些实施方案中提供了确定免疫调节化合物的功效的方法。

公开(公告)号：US10996215B2

公开(公告)日：2021-05-04

申请号：US15946618

申请日：2018-04-05

申请人： CELGENE CORPORATION

发明人： Matthew William Burnell Trotter ,  Patrick Hagner ,  Courtney G. Havens ,  Rajesh Chopra ,  Anita Gandhi ,  Anke Klippel ,  Maria Yinglin Wang ,  Mike Breider ,  Suzana Sturlini Couto ,  Yan Ren ,  Paul Hollenbach ,  Kyle Macbeth

IPC分类号： G01N33/50 ,  A61K31/517 ,  G01N33/68 ,  A61K31/454 ,  A61K31/5377 ,  A61K38/21 ,  C12Q1/6883 ,  C12Q1/6886 ,  G01N33/574

摘要： Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.